الفهرس 
INTRODUCTION
AIM OF THE WORKOnly 14 pages are availabe for public view
 |  | from | 141 |  |  |
| | | from | 141 | | |
Abstract
We conducted retrospective study for all the patients with AML who treated at SECI from January 2000 to December 2010. Data of ninety patients were available. We analyzed characters of the patients, chemotherapeutic regimens and response to treatment. We found AML occurs at younger age (37.9 ± 6.9 years). Standard regimen for induction of remission used in young adults other than M3 was 3 & 7 regimen in which Doxorubicin 25 mg/m2 was the main anthracyclin used. Sixty nine percent of patients showed remission which is comparable to response rate reported with other types of anthracyclin providing evidence that Doxorubicin could be a suitable and effective alternative to other more expensive anthracyclins. Fifty five percent of patients showed remission after first induction which proved to be an important prognostic factor for
patients’ survival. Twenty one percent patients received consolidation in the form of HAM; giving the patients up to one and half years of relapse free duration, while waiting for bone marrow transplantation.